by | Jun 14, 2021 | Twitter
CONGRESS|#EHA2021| Philip Moreau from University Hospital of Nantes, France presented results from CASSIOPEIA study, #mmsm #myeloma https://t.co/q93ASi61mm— Multiple Myeloma Hub (@MM_Hub) June 14, 2021
by | Jun 14, 2021 | Twitter
CONGRESS|#EHA2021|Efstathios Kastritis shared results from ANDROMEDA study. #amyloidosis #mmsm @uoaofficial https://t.co/6LiYJNgctE— Multiple Myeloma Hub (@MM_Hub) June 14, 2021
by | Jun 14, 2021 | Twitter
CONGRESS|#EHA2021| Stefania Oliva, University of Torino, debated & favored the idea about tailoring treatment based on minimal residual disease in MM. #mmsm, #myeloma pic.twitter.com/g2ifhKzk08— Multiple Myeloma Hub (@MM_Hub) June 14, 2021
by | Jun 14, 2021 | Twitter
CONGRESS|#EHA2021| Meletios Dimopolous, discussed treatment for R/R myeloma pts. Rd based regimen should be given to pts receiving bortezomib upfront w/o lenolidomide/daratumumab. Lenalidomide refractory pts could get PomVD, DaraKd, IsakKd/Dara Vd #mmsm #myeloma...
by | Jun 13, 2021 | Twitter
CONGRESS|#EHA2021|@profghjackson, also compared results from various trials to explain benefits of combination therapy #mmsm,#myeloma,University of Newcastle upon Tyne pic.twitter.com/ob46tbi7by— Multiple Myeloma Hub (@MM_Hub) June 12, 2021
by | Jun 13, 2021 | Twitter
CONGRESS|#EHA2021|Samiksha Gupta, University of Oklohoma presented poster on identification of association of high dose therapy-autologous hematopoietic cell transplantation with PFS & OS in high risk MM #mmsm, #myeloma pic.twitter.com/q7YQKkHmgm— Multiple Myeloma...
